Arynta

Overview

lisdexamfetamine

CNS stimulant

• CYP2D6 substrate
• hypertensive effects
• lowers seizure threshold
• serotonergic effects
• tachycardia
• urine pH sensitive

• lisdexamfetamine (prodrug) converted to dextroamphetamine
• add MAO inhibitor to Interaction Check if recent (14 days) use

Contraindicated

• benzphetamine
Arynta (lisdexamfetamine)

+

benzphetamine

1 interaction

Contraindicated

lisdexamfetamine + benzphetamine

contraindicated: combo may incr. risk of tachycardia, HTN, other cardiovascular and CNS stimulatory effects (additive effects, duplicate tx)

• isocarboxazid
Arynta (lisdexamfetamine)

+

isocarboxazid

1 interaction

Contraindicated

lisdexamfetamine + isocarboxazid

contraindicated w/in 14 days of isocarboxazid use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• linezolid
Arynta (lisdexamfetamine)

+

linezolid

1 interaction

Contraindicated

lisdexamfetamine + linezolid

contraindicated w/in 14 days of linezolid use; hold lisdexamfetamine if urgent use; monitor BP, serotonin syndrome sx x2wk after lisdexamfetamine D/C or 24h after last linezolid dose: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects, linezolid reversibly inhibits monoamine oxidase)

• methylene blue injection
Arynta (lisdexamfetamine)

+

methylene blue injection

1 interaction

Contraindicated

lisdexamfetamine + methylene blue injection

contraindicated w/in 14 days of methylene blue use; hold lisdexamfetamine if emergency use; monitor BP, serotonin syndrome sx up to 4h after last methylene blue dose; may resume lisdexamfetamine 72h after last methylene blue dose: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• phendimetrazine
Arynta (lisdexamfetamine)

+

phendimetrazine

1 interaction

Contraindicated

lisdexamfetamine + phendimetrazine

contraindicated: combo may incr. risk of HTN, tachycardia (additive effects)

• phenelzine
Arynta (lisdexamfetamine)

+

phenelzine

1 interaction

Contraindicated

lisdexamfetamine + phenelzine

contraindicated w/in 14 days of phenelzine use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• safinamide
Arynta (lisdexamfetamine)

+

safinamide

1 interaction

Contraindicated

lisdexamfetamine + safinamide

contraindicated w/in 14 days of safinamide use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• selegiline transdermal
Arynta (lisdexamfetamine)

+

selegiline transdermal

1 interaction

Contraindicated

lisdexamfetamine + selegiline transdermal

contraindicated w/in 14 days of selegiline use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• tranylcypromine
Arynta (lisdexamfetamine)

+

tranylcypromine

1 interaction

Contraindicated

lisdexamfetamine + tranylcypromine

contraindicated w/in 14 days of tranylcypromine use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• yohimbe
Arynta (lisdexamfetamine)

+

yohimbe

1 interaction

Contraindicated

lisdexamfetamine + yohimbe

contraindicated w/in 14 days of yohimbe use: combo may incr. risk of serotonin syndrome, HTN (incl. hypertensive crisis), tachycardia (additive effects, yohimbe inhibits monoamine oxidase)

Avoid/Use Alternative

• 5-HTP
Arynta (lisdexamfetamine)

+

5-HTP

1 interaction

Avoid/Use Alternative

lisdexamfetamine + 5-HTP

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• abiraterone acetate
Arynta (lisdexamfetamine)

+

abiraterone acetate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + abiraterone acetate

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• acetazolamide
Arynta (lisdexamfetamine)

+

acetazolamide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + acetazolamide

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects; may alter seizure control (renal excretion decreased at higher urine pH; antagonistic effects, dextroamphetamine may decr. seizure threshold)

• adagrasib
Arynta (lisdexamfetamine)

+

adagrasib

1 interaction

Avoid/Use Alternative

lisdexamfetamine + adagrasib

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• albuterol
Arynta (lisdexamfetamine)

+

albuterol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + albuterol

use alternative or monitor BP, HR w/ oral albuterol; risk may be lower w/ inhaled albuterol: combo may incr. risk of HTN, tachycardia (additive effects)

• aldesleukin
Arynta (lisdexamfetamine)

+

aldesleukin

1 interaction

Avoid/Use Alternative

lisdexamfetamine + aldesleukin

avoid combo: combo may incr. risk of seizures (additive effects)

• alfentanil
Arynta (lisdexamfetamine)

+

alfentanil

1 interaction

Avoid/Use Alternative

lisdexamfetamine + alfentanil

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• almotriptan
Arynta (lisdexamfetamine)

+

almotriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + almotriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• aluminum hydroxide
Arynta (lisdexamfetamine)

+

aluminum hydroxide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + aluminum hydroxide

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• amifampridine
Arynta (lisdexamfetamine)

+

amifampridine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amitriptyline
Arynta (lisdexamfetamine)

+

amitriptyline

1 interaction

Avoid/Use Alternative

lisdexamfetamine + amitriptyline

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• amoxapine
Arynta (lisdexamfetamine)

+

amoxapine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + amoxapine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• amphetamine
Arynta (lisdexamfetamine)

+

amphetamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + amphetamine

consider alternative or decr. start dose of one or both drugs; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• berotralstat
Arynta (lisdexamfetamine)

+

berotralstat

1 interaction

Avoid/Use Alternative

lisdexamfetamine + berotralstat

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• black cohosh
Arynta (lisdexamfetamine)

+

black cohosh

1 interaction

Avoid/Use Alternative

lisdexamfetamine + black cohosh

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• bromocriptine
Arynta (lisdexamfetamine)

+

bromocriptine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + bromocriptine

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• buprenorphine
Arynta (lisdexamfetamine)

+

buprenorphine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + buprenorphine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• bupropion
Arynta (lisdexamfetamine)

+

bupropion

1 interaction

Avoid/Use Alternative

lisdexamfetamine + bupropion

use alternative or decr. lisdexamfetamine start dose, consider lower bupropion doses; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, seizures, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• buspirone
Arynta (lisdexamfetamine)

+

buspirone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + buspirone

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• butorphanol
Arynta (lisdexamfetamine)

+

butorphanol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + butorphanol

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• calcium carbonate
Arynta (lisdexamfetamine)

+

calcium carbonate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + calcium carbonate

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• capivasertib
Arynta (lisdexamfetamine)

+

capivasertib

1 interaction

Avoid/Use Alternative

lisdexamfetamine + capivasertib

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• carbamazepine
Arynta (lisdexamfetamine)

+

carbamazepine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + carbamazepine

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome; may alter seizure control (additive effects; antagonistic effects, dextroamphetamine may decr. seizure threshold)

• cinacalcet
Arynta (lisdexamfetamine)

+

cinacalcet

1 interaction

Avoid/Use Alternative

lisdexamfetamine + cinacalcet

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• citalopram
Arynta (lisdexamfetamine)

+

citalopram

1 interaction

Avoid/Use Alternative

lisdexamfetamine + citalopram

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• clomipramine
Arynta (lisdexamfetamine)

+

clomipramine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + clomipramine

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, seizures, HTN, tachycardia (additive effects)

• cocaine
Arynta (lisdexamfetamine)

+

cocaine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + cocaine

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, tachycardia, serotonin syndrome, seizures (additive effects)

• codeine
Arynta (lisdexamfetamine)

+

codeine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + codeine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• cyclobenzaprine
Arynta (lisdexamfetamine)

+

cyclobenzaprine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + cyclobenzaprine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dacomitinib
Arynta (lisdexamfetamine)

+

dacomitinib

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dacomitinib

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• desipramine
Arynta (lisdexamfetamine)

+

desipramine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + desipramine

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• desvenlafaxine
Arynta (lisdexamfetamine)

+

desvenlafaxine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + desvenlafaxine

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• dexmethylphenidate
Arynta (lisdexamfetamine)

+

dexmethylphenidate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dexmethylphenidate

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• dextroamphetamine
Arynta (lisdexamfetamine)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dextroamphetamine

consider alternative or decr. start dose of one or both drugs; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• dextromethorphan
Arynta (lisdexamfetamine)

+

dextromethorphan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dextromethorphan

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dichlorphenamide
Arynta (lisdexamfetamine)

+

dichlorphenamide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dichlorphenamide

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• dihydrocodeine
Arynta (lisdexamfetamine)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dihydrocodeine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dihydroergotamine
Arynta (lisdexamfetamine)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dihydroergotamine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of severe HTN, vasospasm, ischemia, serotonin syndrome (additive effects)

• doxepin
Arynta (lisdexamfetamine)

+

doxepin

1 interaction

Avoid/Use Alternative

lisdexamfetamine + doxepin

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• doxepin topical
Arynta (lisdexamfetamine)

+

doxepin topical

1 interaction

Avoid/Use Alternative

lisdexamfetamine + doxepin topical

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dronabinol
Arynta (lisdexamfetamine)

+

dronabinol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + dronabinol

avoid combo: combo may incr. risk of HTN, tachycardia (additive effects)

• duloxetine
Arynta (lisdexamfetamine)

+

duloxetine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + duloxetine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited, additive effects)

• eletriptan
Arynta (lisdexamfetamine)

+

eletriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + eletriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• eliglustat
Arynta (lisdexamfetamine)

+

eliglustat

1 interaction

Avoid/Use Alternative

lisdexamfetamine + eliglustat

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• ephedra
Arynta (lisdexamfetamine)

+

ephedra

1 interaction

Avoid/Use Alternative

lisdexamfetamine + ephedra

avoid combo: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• epinephrine inhaled
Arynta (lisdexamfetamine)

+

epinephrine inhaled

1 interaction

Avoid/Use Alternative

lisdexamfetamine + epinephrine inhaled

avoid combo: combo may incr. risk of HTN (incl. hypertensive crisis), tachycardia (additive effects)

• ergotamine
Arynta (lisdexamfetamine)

+

ergotamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + ergotamine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of severe HTN, vasospasm, ischemia, serotonin syndrome (additive effects)

• escitalopram
Arynta (lisdexamfetamine)

+

escitalopram

1 interaction

Avoid/Use Alternative

lisdexamfetamine + escitalopram

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• fedratinib
Arynta (lisdexamfetamine)

+

fedratinib

1 interaction

Avoid/Use Alternative

lisdexamfetamine + fedratinib

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• fenfluramine
Arynta (lisdexamfetamine)

+

fenfluramine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + fenfluramine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN (incl. hypertensive crisis), serotonin syndrome; may alter seizure control (additive effects; antagonistic effects, dextroamphetamine may decr. seizure threshold)

• fentanyl
Arynta (lisdexamfetamine)

+

fentanyl

1 interaction

Avoid/Use Alternative

lisdexamfetamine + fentanyl

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• fluoxetine
Arynta (lisdexamfetamine)

+

fluoxetine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + fluoxetine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited, additive effects)

• fluvoxamine
Arynta (lisdexamfetamine)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + fluvoxamine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• frovatriptan
Arynta (lisdexamfetamine)

+

frovatriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + frovatriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• furosemide
Arynta (lisdexamfetamine)

+

furosemide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + furosemide

use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• gepirone
Arynta (lisdexamfetamine)

+

gepirone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + gepirone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• givosiran
Arynta (lisdexamfetamine)

+

givosiran

1 interaction

Avoid/Use Alternative

lisdexamfetamine + givosiran

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited; givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• granisetron
Arynta (lisdexamfetamine)

+

granisetron

1 interaction

Avoid/Use Alternative

lisdexamfetamine + granisetron

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• hydrocodone
Arynta (lisdexamfetamine)

+

hydrocodone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + hydrocodone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• hydromorphone
Arynta (lisdexamfetamine)

+

hydromorphone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + hydromorphone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• imipramine
Arynta (lisdexamfetamine)

+

imipramine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + imipramine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• isoniazid
Arynta (lisdexamfetamine)

+

isoniazid

1 interaction

Avoid/Use Alternative

lisdexamfetamine + isoniazid

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, isoniazid inhibits monoamine oxidase)

• landiolol
Arynta (lisdexamfetamine)

+

landiolol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + landiolol

use alternative or monitor HR, BP: combo may decr. landiolol efficacy (antagonistic effects)

• lasmiditan
Arynta (lisdexamfetamine)

+

lasmiditan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + lasmiditan

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• levomilnacipran
Arynta (lisdexamfetamine)

+

levomilnacipran

1 interaction

Avoid/Use Alternative

lisdexamfetamine + levomilnacipran

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• levorphanol
Arynta (lisdexamfetamine)

+

levorphanol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + levorphanol

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• lisdexamfetamine
Arynta (lisdexamfetamine)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + lisdexamfetamine

avoid combo: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• lithium
Arynta (lisdexamfetamine)

+

lithium

1 interaction

Avoid/Use Alternative

lisdexamfetamine + lithium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider decr. lisdexamfetamine start dose: combo may incr. risk of serotonin syndrome; lithium may inhibit anorectic and central stimulant effects of amphetamines (additive effects; antagonistic effects)

• magnesium carbonate
Arynta (lisdexamfetamine)

+

magnesium carbonate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + magnesium carbonate

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• magnesium hydroxide
Arynta (lisdexamfetamine)

+

magnesium hydroxide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + magnesium hydroxide

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• mavorixafor
Arynta (lisdexamfetamine)

+

mavorixafor

1 interaction

Avoid/Use Alternative

lisdexamfetamine + mavorixafor

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• meperidine
Arynta (lisdexamfetamine)

+

meperidine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + meperidine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• metaxalone
Arynta (lisdexamfetamine)

+

metaxalone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + metaxalone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methadone
Arynta (lisdexamfetamine)

+

methadone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + methadone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methamphetamine
Arynta (lisdexamfetamine)

+

methamphetamine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + methamphetamine

consider alternative or decr. start dose of one or both drugs; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• methazolamide
Arynta (lisdexamfetamine)

+

methazolamide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + methazolamide

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• methylene blue oral
Arynta (lisdexamfetamine)

+

methylene blue oral

1 interaction

Avoid/Use Alternative

lisdexamfetamine + methylene blue oral

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• methylergonovine
Arynta (lisdexamfetamine)

+

methylergonovine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + methylergonovine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of severe HTN, vasospasm, ischemia, serotonin syndrome (additive effects)

• methylphenidate
Arynta (lisdexamfetamine)

+

methylphenidate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + methylphenidate

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• metoclopramide
Arynta (lisdexamfetamine)

+

metoclopramide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + metoclopramide

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• metolazone
Arynta (lisdexamfetamine)

+

metolazone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + metolazone

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects; may decr. antihypertensive agent efficacy (renal excretion decreased at higher urine pH; antagonistic effects)

• midodrine
Arynta (lisdexamfetamine)

+

midodrine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + midodrine

use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

• milnacipran
Arynta (lisdexamfetamine)

+

milnacipran

1 interaction

Avoid/Use Alternative

lisdexamfetamine + milnacipran

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• mirabegron
Arynta (lisdexamfetamine)

+

mirabegron

1 interaction

Avoid/Use Alternative

lisdexamfetamine + mirabegron

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• mirtazapine
Arynta (lisdexamfetamine)

+

mirtazapine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + mirtazapine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• morphine
Arynta (lisdexamfetamine)

+

morphine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + morphine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nalbuphine
Arynta (lisdexamfetamine)

+

nalbuphine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + nalbuphine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• naratriptan
Arynta (lisdexamfetamine)

+

naratriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + naratriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• nefazodone
Arynta (lisdexamfetamine)

+

nefazodone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + nefazodone

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nortriptyline
Arynta (lisdexamfetamine)

+

nortriptyline

1 interaction

Avoid/Use Alternative

lisdexamfetamine + nortriptyline

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• oliceridine
Arynta (lisdexamfetamine)

+

oliceridine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + oliceridine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ondansetron
Arynta (lisdexamfetamine)

+

ondansetron

1 interaction

Avoid/Use Alternative

lisdexamfetamine + ondansetron

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• opium
Arynta (lisdexamfetamine)

+

opium

1 interaction

Avoid/Use Alternative

lisdexamfetamine + opium

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• oxycodone
Arynta (lisdexamfetamine)

+

oxycodone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + oxycodone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• oxymorphone
Arynta (lisdexamfetamine)

+

oxymorphone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + oxymorphone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• palonosetron
Arynta (lisdexamfetamine)

+

palonosetron

1 interaction

Avoid/Use Alternative

lisdexamfetamine + palonosetron

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• paroxetine
Arynta (lisdexamfetamine)

+

paroxetine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + paroxetine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited, additive effects)

• pentazocine
Arynta (lisdexamfetamine)

+

pentazocine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + pentazocine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• potassium citrate
Arynta (lisdexamfetamine)

+

potassium citrate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + potassium citrate

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• procarbazine
Arynta (lisdexamfetamine)

+

procarbazine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + procarbazine

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects, procarbazine inhibits monoamine oxidase)

• protriptyline
Arynta (lisdexamfetamine)

+

protriptyline

1 interaction

Avoid/Use Alternative

lisdexamfetamine + protriptyline

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• quinidine (antiarrhythmic)
Arynta (lisdexamfetamine)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

lisdexamfetamine + quinidine (antiarrhythmic)

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• quinidine (CYP2D6 inhibitor)
Arynta (lisdexamfetamine)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

lisdexamfetamine + quinidine (CYP2D6 inhibitor)

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• rasagiline
Arynta (lisdexamfetamine)

+

rasagiline

1 interaction

Avoid/Use Alternative

lisdexamfetamine + rasagiline

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• remifentanil
Arynta (lisdexamfetamine)

+

remifentanil

1 interaction

Avoid/Use Alternative

lisdexamfetamine + remifentanil

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• rizatriptan
Arynta (lisdexamfetamine)

+

rizatriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + rizatriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• rolapitant
Arynta (lisdexamfetamine)

+

rolapitant

1 interaction

Avoid/Use Alternative

lisdexamfetamine + rolapitant

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• SAMe
Arynta (lisdexamfetamine)

+

SAMe

1 interaction

Avoid/Use Alternative

lisdexamfetamine + SAMe

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• selegiline
Arynta (lisdexamfetamine)

+

selegiline

1 interaction

Avoid/Use Alternative

lisdexamfetamine + selegiline

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• sertraline
Arynta (lisdexamfetamine)

+

sertraline

1 interaction

Avoid/Use Alternative

lisdexamfetamine + sertraline

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sodium bicarbonate
Arynta (lisdexamfetamine)

+

sodium bicarbonate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + sodium bicarbonate

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• sodium citrate
Arynta (lisdexamfetamine)

+

sodium citrate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + sodium citrate

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (renal excretion decreased at higher urine pH)

• St. John's wort
Arynta (lisdexamfetamine)

+

St. John's wort

1 interaction

Avoid/Use Alternative

lisdexamfetamine + St. John's wort

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sufentanil
Arynta (lisdexamfetamine)

+

sufentanil

1 interaction

Avoid/Use Alternative

lisdexamfetamine + sufentanil

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sumatriptan
Arynta (lisdexamfetamine)

+

sumatriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + sumatriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• tapentadol
Arynta (lisdexamfetamine)

+

tapentadol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + tapentadol

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• terbinafine
Arynta (lisdexamfetamine)

+

terbinafine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + terbinafine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• thioridazine
Arynta (lisdexamfetamine)

+

thioridazine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + thioridazine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• tipranavir
Arynta (lisdexamfetamine)

+

tipranavir

1 interaction

Avoid/Use Alternative

lisdexamfetamine + tipranavir

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. inhibited)

• topiramate
Arynta (lisdexamfetamine)

+

topiramate

1 interaction

Avoid/Use Alternative

lisdexamfetamine + topiramate

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects; may alter seizure control (renal excretion decreased at higher urine pH; antagonistic effects, dextroamphetamine may decr. seizure threshold)

• tramadol
Arynta (lisdexamfetamine)

+

tramadol

1 interaction

Avoid/Use Alternative

lisdexamfetamine + tramadol

use alternative or decr. lisdexamfetamine dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, seizures (additive effects)

• trazodone
Arynta (lisdexamfetamine)

+

trazodone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + trazodone

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• trimipramine
Arynta (lisdexamfetamine)

+

trimipramine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + trimipramine

use alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• venlafaxine
Arynta (lisdexamfetamine)

+

venlafaxine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + venlafaxine

use alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• vilazodone
Arynta (lisdexamfetamine)

+

vilazodone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + vilazodone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• vortioxetine
Arynta (lisdexamfetamine)

+

vortioxetine

1 interaction

Avoid/Use Alternative

lisdexamfetamine + vortioxetine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ziprasidone
Arynta (lisdexamfetamine)

+

ziprasidone

1 interaction

Avoid/Use Alternative

lisdexamfetamine + ziprasidone

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• zolmitriptan
Arynta (lisdexamfetamine)

+

zolmitriptan

1 interaction

Avoid/Use Alternative

lisdexamfetamine + zolmitriptan

consider alternative or decr. lisdexamfetamine start dose; monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• zonisamide
Arynta (lisdexamfetamine)

+

zonisamide

1 interaction

Avoid/Use Alternative

lisdexamfetamine + zonisamide

avoid combo: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects; may alter seizure control (renal excretion decreased at higher urine pH; antagonistic effects, dextroamphetamine may decr. seizure threshold)

Monitor/Modify Tx

• acebutolol
Arynta (lisdexamfetamine)

+

acebutolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + acebutolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• albuterol inhaled
Arynta (lisdexamfetamine)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + albuterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• aliskiren
Arynta (lisdexamfetamine)

+

aliskiren

1 interaction

Monitor/Modify Tx

lisdexamfetamine + aliskiren

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• amiloride
Arynta (lisdexamfetamine)

+

amiloride

1 interaction

Monitor/Modify Tx

lisdexamfetamine + amiloride

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• amlodipine
Arynta (lisdexamfetamine)

+

amlodipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + amlodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• angiotensin II
Arynta (lisdexamfetamine)

+

angiotensin II

1 interaction

Monitor/Modify Tx

lisdexamfetamine + angiotensin II

monitor BP: combo may incr. risk of HTN (additive effects)

• aprocitentan
Arynta (lisdexamfetamine)

+

aprocitentan

1 interaction

Monitor/Modify Tx

lisdexamfetamine + aprocitentan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• arformoterol inhaled
Arynta (lisdexamfetamine)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + arformoterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• armodafinil
Arynta (lisdexamfetamine)

+

armodafinil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + armodafinil

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• asciminib
Arynta (lisdexamfetamine)

+

asciminib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + asciminib

monitor BP: combo may incr. risk of HTN (additive effects)

• atenolol
Arynta (lisdexamfetamine)

+

atenolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + atenolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• atogepant
Arynta (lisdexamfetamine)

+

atogepant

1 interaction

Monitor/Modify Tx

lisdexamfetamine + atogepant

monitor BP: combo may incr. risk of HTN (additive effects)

• atomoxetine
Arynta (lisdexamfetamine)

+

atomoxetine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + atomoxetine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• atropine
Arynta (lisdexamfetamine)

+

atropine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + atropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• atropine ophthalmic
Arynta (lisdexamfetamine)

+

atropine ophthalmic

1 interaction

Monitor/Modify Tx

lisdexamfetamine + atropine ophthalmic

monitor BP: combo may incr. risk of HTN (additive effects)

• axitinib
Arynta (lisdexamfetamine)

+

axitinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + axitinib

monitor BP: combo may incr. risk of HTN (additive effects)

• azilsartan medoxomil
Arynta (lisdexamfetamine)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + azilsartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• benazepril
Arynta (lisdexamfetamine)

+

benazepril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + benazepril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• benztropine
Arynta (lisdexamfetamine)

+

benztropine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + benztropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• betamethasone
Arynta (lisdexamfetamine)

+

betamethasone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + betamethasone

monitor BP: combo may incr. risk of HTN (additive effects)

• betaxolol
Arynta (lisdexamfetamine)

+

betaxolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + betaxolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• bevacizumab
Arynta (lisdexamfetamine)

+

bevacizumab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + bevacizumab

monitor BP: combo may incr. risk of HTN (additive effects)

• bismuth subsalicylate
Arynta (lisdexamfetamine)

+

bismuth subsalicylate

1 interaction

Monitor/Modify Tx

lisdexamfetamine + bismuth subsalicylate

monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

• bisoprolol
Arynta (lisdexamfetamine)

+

bisoprolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + bisoprolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• brigatinib
Arynta (lisdexamfetamine)

+

brigatinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + brigatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• budesonide
Arynta (lisdexamfetamine)

+

budesonide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + budesonide

monitor BP: combo may incr. risk of HTN (additive effects)

• bumetanide
Arynta (lisdexamfetamine)

+

bumetanide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + bumetanide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• cabozantinib
Arynta (lisdexamfetamine)

+

cabozantinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + cabozantinib

monitor BP: combo may incr. risk of HTN (additive effects)

• caffeine
Arynta (lisdexamfetamine)

+

caffeine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + caffeine

monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects)

• caffeine citrate
Arynta (lisdexamfetamine)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

lisdexamfetamine + caffeine citrate

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• candesartan cilexetil
Arynta (lisdexamfetamine)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + candesartan cilexetil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• cannabis
Arynta (lisdexamfetamine)

+

cannabis

1 interaction

Monitor/Modify Tx

lisdexamfetamine + cannabis

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• captopril
Arynta (lisdexamfetamine)

+

captopril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + captopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• carfilzomib
Arynta (lisdexamfetamine)

+

carfilzomib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + carfilzomib

monitor BP: combo may incr. risk of HTN (additive effects)

• carvedilol
Arynta (lisdexamfetamine)

+

carvedilol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + carvedilol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• celecoxib
Arynta (lisdexamfetamine)

+

celecoxib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + celecoxib

monitor BP: combo may incr. risk of HTN (additive effects)

• chlorothiazide
Arynta (lisdexamfetamine)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + chlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• chlorthalidone
Arynta (lisdexamfetamine)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + chlorthalidone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clevidipine
Arynta (lisdexamfetamine)

+

clevidipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + clevidipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clonidine
Arynta (lisdexamfetamine)

+

clonidine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + clonidine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• copanlisib
Arynta (lisdexamfetamine)

+

copanlisib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + copanlisib

monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

• corticotropin
Arynta (lisdexamfetamine)

+

corticotropin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + corticotropin

monitor BP: combo may incr. risk of HTN (additive effects)

• cortisone
Arynta (lisdexamfetamine)

+

cortisone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + cortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• cyclosporine
Arynta (lisdexamfetamine)

+

cyclosporine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + cyclosporine

monitor BP: combo may incr. risk of HTN (additive effects)

• danazol
Arynta (lisdexamfetamine)

+

danazol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + danazol

monitor BP: combo may incr. risk of HTN (additive effects)

• darbepoetin alfa
Arynta (lisdexamfetamine)

+

darbepoetin alfa

1 interaction

Monitor/Modify Tx

lisdexamfetamine + darbepoetin alfa

monitor BP: combo may incr. risk of HTN (additive effects)

• deflazacort
Arynta (lisdexamfetamine)

+

deflazacort

1 interaction

Monitor/Modify Tx

lisdexamfetamine + deflazacort

monitor BP: combo may incr. risk of HTN (additive effects)

• desflurane
Arynta (lisdexamfetamine)

+

desflurane

1 interaction

Monitor/Modify Tx

lisdexamfetamine + desflurane

consider D/C lisdexamfetamine day of surgery: combo may incr. risk of intraoperative HTN, tachycardia (mechanism unknown)

• desmopressin
Arynta (lisdexamfetamine)

+

desmopressin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + desmopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• dexamethasone
Arynta (lisdexamfetamine)

+

dexamethasone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + dexamethasone

monitor BP: combo may incr. risk of HTN (additive effects)

• diclofenac
Arynta (lisdexamfetamine)

+

diclofenac

1 interaction

Monitor/Modify Tx

lisdexamfetamine + diclofenac

monitor BP: combo may incr. risk of HTN (additive effects)

• diclofenac topical
Arynta (lisdexamfetamine)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

lisdexamfetamine + diclofenac topical

monitor BP: combo may incr. risk of HTN (additive effects)

• dicyclomine
Arynta (lisdexamfetamine)

+

dicyclomine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + dicyclomine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• diethylpropion
Arynta (lisdexamfetamine)

+

diethylpropion

1 interaction

Monitor/Modify Tx

lisdexamfetamine + diethylpropion

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• diflunisal
Arynta (lisdexamfetamine)

+

diflunisal

1 interaction

Monitor/Modify Tx

lisdexamfetamine + diflunisal

monitor BP: combo may incr. risk of HTN (additive effects)

• diltiazem
Arynta (lisdexamfetamine)

+

diltiazem

1 interaction

Monitor/Modify Tx

lisdexamfetamine + diltiazem

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• dobutamine
Arynta (lisdexamfetamine)

+

dobutamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + dobutamine

monitor BP, HR: combo may incr. risk of HTN, hypertensive crisis, tachycardia, other cardiac arrhythmias (additive effects)

• dopamine
Arynta (lisdexamfetamine)

+

dopamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + dopamine

monitor BP, HR: combo may incr. risk of HTN, hypertensive crisis, tachycardia, other cardiac arrhythmias (additive effects)

• doxapram
Arynta (lisdexamfetamine)

+

doxapram

1 interaction

Monitor/Modify Tx

lisdexamfetamine + doxapram

monitor BP: combo may incr. risk of HTN (additive effects)

• doxazosin
Arynta (lisdexamfetamine)

+

doxazosin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + doxazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• droxidopa
Arynta (lisdexamfetamine)

+

droxidopa

1 interaction

Monitor/Modify Tx

lisdexamfetamine + droxidopa

monitor BP: combo may incr. risk of supine HTN (additive effects)

• enalapril
Arynta (lisdexamfetamine)

+

enalapril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + enalapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• enalaprilat
Arynta (lisdexamfetamine)

+

enalaprilat

1 interaction

Monitor/Modify Tx

lisdexamfetamine + enalaprilat

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• enzalutamide
Arynta (lisdexamfetamine)

+

enzalutamide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + enzalutamide

monitor BP: combo may incr. risk of HTN (additive effects)

• ephedrine injection
Arynta (lisdexamfetamine)

+

ephedrine injection

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ephedrine injection

monitor BP, HR: combo may incr. risk of HTN, tachycardia, cardiac arrhythmias (additive effects)

• ephedrine oral
Arynta (lisdexamfetamine)

+

ephedrine oral

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ephedrine oral

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• epinephrine
Arynta (lisdexamfetamine)

+

epinephrine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + epinephrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• eplerenone
Arynta (lisdexamfetamine)

+

eplerenone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + eplerenone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• epoetin alfa
Arynta (lisdexamfetamine)

+

epoetin alfa

1 interaction

Monitor/Modify Tx

lisdexamfetamine + epoetin alfa

monitor BP: combo may incr. risk of HTN (additive effects)

• eptinezumab
Arynta (lisdexamfetamine)

+

eptinezumab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + eptinezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• erenumab
Arynta (lisdexamfetamine)

+

erenumab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + erenumab

monitor BP: combo may incr. risk of HTN (additive effects)

• esketamine
Arynta (lisdexamfetamine)

+

esketamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + esketamine

monitor BP: combo may incr. risk of HTN (additive effects)

• esmolol
Arynta (lisdexamfetamine)

+

esmolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + esmolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• estetrol (contraceptive)
Arynta (lisdexamfetamine)

+

estetrol (contraceptive)

1 interaction

Monitor/Modify Tx

lisdexamfetamine + estetrol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• estradiol (contraceptive)
Arynta (lisdexamfetamine)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

lisdexamfetamine + estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• ethacrynic acid
Arynta (lisdexamfetamine)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ethacrynic acid

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ethinyl estradiol (contraceptive)
Arynta (lisdexamfetamine)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ethinyl estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• etodolac
Arynta (lisdexamfetamine)

+

etodolac

1 interaction

Monitor/Modify Tx

lisdexamfetamine + etodolac

monitor BP: combo may incr. risk of HTN (additive effects)

• etrasimod
Arynta (lisdexamfetamine)

+

etrasimod

1 interaction

Monitor/Modify Tx

lisdexamfetamine + etrasimod

monitor BP: combo may incr. risk of HTN (additive effects)

• felodipine
Arynta (lisdexamfetamine)

+

felodipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + felodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenoldopam
Arynta (lisdexamfetamine)

+

fenoldopam

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fenoldopam

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenoprofen
Arynta (lisdexamfetamine)

+

fenoprofen

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fenoprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• fingolimod
Arynta (lisdexamfetamine)

+

fingolimod

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fingolimod

monitor BP: combo may incr. risk of HTN (additive effects)

• fludrocortisone
Arynta (lisdexamfetamine)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fludrocortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• flurbiprofen
Arynta (lisdexamfetamine)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

lisdexamfetamine + flurbiprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• formoterol inhaled
Arynta (lisdexamfetamine)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + formoterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• fosinopril
Arynta (lisdexamfetamine)

+

fosinopril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fosinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fostamatinib
Arynta (lisdexamfetamine)

+

fostamatinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fostamatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• fremanezumab
Arynta (lisdexamfetamine)

+

fremanezumab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fremanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• fruquintinib
Arynta (lisdexamfetamine)

+

fruquintinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + fruquintinib

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• galcanezumab
Arynta (lisdexamfetamine)

+

galcanezumab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + galcanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• glycopyrrolate
Arynta (lisdexamfetamine)

+

glycopyrrolate

1 interaction

Monitor/Modify Tx

lisdexamfetamine + glycopyrrolate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• guanfacine
Arynta (lisdexamfetamine)

+

guanfacine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + guanfacine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hoodia
Arynta (lisdexamfetamine)

+

hoodia

1 interaction

Monitor/Modify Tx

lisdexamfetamine + hoodia

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• hydralazine
Arynta (lisdexamfetamine)

+

hydralazine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + hydralazine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrochlorothiazide
Arynta (lisdexamfetamine)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + hydrochlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrocortisone
Arynta (lisdexamfetamine)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + hydrocortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• hyoscyamine
Arynta (lisdexamfetamine)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + hyoscyamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ibrutinib
Arynta (lisdexamfetamine)

+

ibrutinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ibrutinib

monitor BP: combo may incr. risk of HTN (additive effects)

• ibuprofen
Arynta (lisdexamfetamine)

+

ibuprofen

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ibuprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• indapamide
Arynta (lisdexamfetamine)

+

indapamide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + indapamide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• indomethacin
Arynta (lisdexamfetamine)

+

indomethacin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + indomethacin

monitor BP: combo may incr. risk of HTN (additive effects)

• iohexol
Arynta (lisdexamfetamine)

+

iohexol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + iohexol

if intrathecal iohexol use, D/C lisdexamfetamine at least 48h before myelography, may resume at least 24h after procedure: combo may incr. risk of seizures (additive effects)

• iopamidol
Arynta (lisdexamfetamine)

+

iopamidol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + iopamidol

caution advised if intrathecal iopamidol use; consider holding lisdexamfetamine at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irbesartan
Arynta (lisdexamfetamine)

+

irbesartan

1 interaction

Monitor/Modify Tx

lisdexamfetamine + irbesartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• isoflurane
Arynta (lisdexamfetamine)

+

isoflurane

1 interaction

Monitor/Modify Tx

lisdexamfetamine + isoflurane

consider D/C lisdexamfetamine day of surgery: combo may incr. risk of intraoperative HTN, tachycardia (mechanism unknown)

• isoproterenol
Arynta (lisdexamfetamine)

+

isoproterenol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + isoproterenol

monitor HR: combo may incr. risk of tachycardia (additive effects)

• isradipine
Arynta (lisdexamfetamine)

+

isradipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + isradipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ketamine
Arynta (lisdexamfetamine)

+

ketamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ketamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other sympathomimetic adverse effects (additive effects)

• ketoprofen
Arynta (lisdexamfetamine)

+

ketoprofen

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ketoprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• ketorolac
Arynta (lisdexamfetamine)

+

ketorolac

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ketorolac

monitor BP: combo may incr. risk of HTN (additive effects)

• labetalol
Arynta (lisdexamfetamine)

+

labetalol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + labetalol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lanreotide
Arynta (lisdexamfetamine)

+

lanreotide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + lanreotide

monitor BP: combo may incr. risk of HTN (additive effects)

• leflunomide
Arynta (lisdexamfetamine)

+

leflunomide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + leflunomide

monitor BP: combo may incr. risk of HTN (additive effects)

• lenvatinib
Arynta (lisdexamfetamine)

+

lenvatinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + lenvatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• levalbuterol inhaled
Arynta (lisdexamfetamine)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + levalbuterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• levothyroxine
Arynta (lisdexamfetamine)

+

levothyroxine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + levothyroxine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• licorice
Arynta (lisdexamfetamine)

+

licorice

1 interaction

Monitor/Modify Tx

lisdexamfetamine + licorice

monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects)

• lifileucel
Arynta (lisdexamfetamine)

+

lifileucel

1 interaction

Monitor/Modify Tx

lisdexamfetamine + lifileucel

monitor HR: combo may incr. risk of tachycardia (additive effects)

• liothyronine
Arynta (lisdexamfetamine)

+

liothyronine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + liothyronine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• liraglutide
Arynta (lisdexamfetamine)

+

liraglutide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + liraglutide

monitor HR: combo may incr. risk of tachycardia (additive effects)

• lisinopril
Arynta (lisdexamfetamine)

+

lisinopril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + lisinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lorlatinib
Arynta (lisdexamfetamine)

+

lorlatinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + lorlatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• losartan
Arynta (lisdexamfetamine)

+

losartan

1 interaction

Monitor/Modify Tx

lisdexamfetamine + losartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lumacaftor/ivacaftor
Arynta (lisdexamfetamine)

+

lumacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

lisdexamfetamine + lumacaftor/ ivacaftor

monitor BP: combo may incr. risk of HTN (additive effects)

• luspatercept
Arynta (lisdexamfetamine)

+

luspatercept

1 interaction

Monitor/Modify Tx

lisdexamfetamine + luspatercept

monitor BP: combo may incr. risk of HTN (additive effects)

• magnesium salicylate
Arynta (lisdexamfetamine)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

lisdexamfetamine + magnesium salicylate

monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

• meclofenamate
Arynta (lisdexamfetamine)

+

meclofenamate

1 interaction

Monitor/Modify Tx

lisdexamfetamine + meclofenamate

monitor BP: combo may incr. risk of HTN (additive effects)

• mefenamic acid
Arynta (lisdexamfetamine)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

lisdexamfetamine + mefenamic acid

monitor BP: combo may incr. risk of HTN (additive effects)

• meloxicam
Arynta (lisdexamfetamine)

+

meloxicam

1 interaction

Monitor/Modify Tx

lisdexamfetamine + meloxicam

monitor BP: combo may incr. risk of HTN (additive effects)

• methoxy polyethylene glycol-epoetin beta
Arynta (lisdexamfetamine)

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Monitor/Modify Tx

lisdexamfetamine + methoxy polyethylene glycol-epoetin beta

monitor BP: combo may incr. risk of HTN (additive effects)

• methscopolamine
Arynta (lisdexamfetamine)

+

methscopolamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + methscopolamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• methyldopa
Arynta (lisdexamfetamine)

+

methyldopa

1 interaction

Monitor/Modify Tx

lisdexamfetamine + methyldopa

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• methylprednisolone
Arynta (lisdexamfetamine)

+

methylprednisolone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + methylprednisolone

monitor BP: combo may incr. risk of HTN (additive effects)

• methyltestosterone
Arynta (lisdexamfetamine)

+

methyltestosterone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + methyltestosterone

monitor BP: combo may incr. risk of HTN (additive effects)

• metoprolol
Arynta (lisdexamfetamine)

+

metoprolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + metoprolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• minoxidil
Arynta (lisdexamfetamine)

+

minoxidil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + minoxidil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• modafinil
Arynta (lisdexamfetamine)

+

modafinil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + modafinil

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• moexipril
Arynta (lisdexamfetamine)

+

moexipril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + moexipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nabumetone
Arynta (lisdexamfetamine)

+

nabumetone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nabumetone

monitor BP: combo may incr. risk of HTN (additive effects)

• nadolol
Arynta (lisdexamfetamine)

+

nadolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nadolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• naproxen
Arynta (lisdexamfetamine)

+

naproxen

1 interaction

Monitor/Modify Tx

lisdexamfetamine + naproxen

monitor BP: combo may incr. risk of HTN (additive effects)

• naxitamab
Arynta (lisdexamfetamine)

+

naxitamab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + naxitamab

monitor BP: combo may incr. risk of HTN (additive effects)

• nebivolol
Arynta (lisdexamfetamine)

+

nebivolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nebivolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nicardipine
Arynta (lisdexamfetamine)

+

nicardipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nicardipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nifedipine
Arynta (lisdexamfetamine)

+

nifedipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nifedipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nimodipine
Arynta (lisdexamfetamine)

+

nimodipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nimodipine

monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

• niraparib
Arynta (lisdexamfetamine)

+

niraparib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + niraparib

monitor BP: combo may incr. risk of HTN (additive effects)

• nisoldipine
Arynta (lisdexamfetamine)

+

nisoldipine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + nisoldipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• norepinephrine
Arynta (lisdexamfetamine)

+

norepinephrine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + norepinephrine

monitor BP: combo may incr. risk of severe HTN (additive effects)

• olmesartan medoxomil
Arynta (lisdexamfetamine)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + olmesartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• olodaterol inhaled
Arynta (lisdexamfetamine)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + olodaterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• orphenadrine
Arynta (lisdexamfetamine)

+

orphenadrine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + orphenadrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• osilodrostat
Arynta (lisdexamfetamine)

+

osilodrostat

1 interaction

Monitor/Modify Tx

lisdexamfetamine + osilodrostat

monitor BP: combo may incr. risk of HTN (additive effects)

• oxaprozin
Arynta (lisdexamfetamine)

+

oxaprozin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + oxaprozin

monitor BP: combo may incr. risk of HTN (additive effects)

• oxymetazoline nasal
Arynta (lisdexamfetamine)

+

oxymetazoline nasal

1 interaction

Monitor/Modify Tx

lisdexamfetamine + oxymetazoline nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• oxytocin
Arynta (lisdexamfetamine)

+

oxytocin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + oxytocin

monitor BP: combo may incr. risk of HTN, incl. life-threatening (additive effects)

• ozanimod
Arynta (lisdexamfetamine)

+

ozanimod

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ozanimod

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• pazopanib
Arynta (lisdexamfetamine)

+

pazopanib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + pazopanib

monitor BP: combo may incr. risk of HTN (additive effects)

• perindopril
Arynta (lisdexamfetamine)

+

perindopril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + perindopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• pexidartinib
Arynta (lisdexamfetamine)

+

pexidartinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + pexidartinib

monitor BP: combo may incr. risk of HTN (additive effects)

• phenoxybenzamine
Arynta (lisdexamfetamine)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phenoxybenzamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phentermine
Arynta (lisdexamfetamine)

+

phentermine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phentermine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, CNS stimulatory effects (additive effects)

• phentolamine
Arynta (lisdexamfetamine)

+

phentolamine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phentolamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phenylephrine
Arynta (lisdexamfetamine)

+

phenylephrine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phenylephrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular and CNS stimulatory effects (additive effects)

• phenylephrine injection
Arynta (lisdexamfetamine)

+

phenylephrine injection

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phenylephrine injection

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine nasal
Arynta (lisdexamfetamine)

+

phenylephrine nasal

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phenylephrine nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine ophthalmic
Arynta (lisdexamfetamine)

+

phenylephrine ophthalmic

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phenylephrine ophthalmic

monitor BP, HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN, tachycardia (additive effects)

• phenylephrine rectal
Arynta (lisdexamfetamine)

+

phenylephrine rectal

1 interaction

Monitor/Modify Tx

lisdexamfetamine + phenylephrine rectal

monitor BP: combo may incr. risk of HTN (additive effects)

• pindolol
Arynta (lisdexamfetamine)

+

pindolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + pindolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• piroxicam
Arynta (lisdexamfetamine)

+

piroxicam

1 interaction

Monitor/Modify Tx

lisdexamfetamine + piroxicam

monitor BP: combo may incr. risk of HTN (additive effects)

• ponatinib
Arynta (lisdexamfetamine)

+

ponatinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ponatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• ponesimod
Arynta (lisdexamfetamine)

+

ponesimod

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ponesimod

monitor BP: combo may incr. risk of HTN (additive effects)

• pralsetinib
Arynta (lisdexamfetamine)

+

pralsetinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + pralsetinib

monitor BP: combo may incr. risk of HTN (additive effects)

• prazosin
Arynta (lisdexamfetamine)

+

prazosin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + prazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• prednisolone
Arynta (lisdexamfetamine)

+

prednisolone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + prednisolone

monitor BP: combo may incr. risk of HTN (additive effects)

• prednisone
Arynta (lisdexamfetamine)

+

prednisone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + prednisone

monitor BP: combo may incr. risk of HTN (additive effects)

• propranolol
Arynta (lisdexamfetamine)

+

propranolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + propranolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• pseudoephedrine
Arynta (lisdexamfetamine)

+

pseudoephedrine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + pseudoephedrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular and CNS stimulatory effects (additive effects)

• quetiapine
Arynta (lisdexamfetamine)

+

quetiapine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + quetiapine

monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

• quinapril
Arynta (lisdexamfetamine)

+

quinapril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + quinapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ramipril
Arynta (lisdexamfetamine)

+

ramipril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ramipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ramucirumab
Arynta (lisdexamfetamine)

+

ramucirumab

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ramucirumab

monitor BP: combo may incr. risk of HTN (additive effects)

• regorafenib
Arynta (lisdexamfetamine)

+

regorafenib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + regorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

• rimegepant
Arynta (lisdexamfetamine)

+

rimegepant

1 interaction

Monitor/Modify Tx

lisdexamfetamine + rimegepant

monitor BP: combo may incr. risk of HTN (additive effects)

• ripretinib
Arynta (lisdexamfetamine)

+

ripretinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ripretinib

monitor BP: combo may incr. risk of HTN (additive effects)

• ritonavir
Arynta (lisdexamfetamine)

+

ritonavir

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ritonavir

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metab. possibly inhibited)

• ropinirole
Arynta (lisdexamfetamine)

+

ropinirole

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ropinirole

monitor BP: combo may incr. risk of HTN (additive effects)

• rotigotine transdermal
Arynta (lisdexamfetamine)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

lisdexamfetamine + rotigotine transdermal

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• salmeterol inhaled
Arynta (lisdexamfetamine)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + salmeterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• salsalate
Arynta (lisdexamfetamine)

+

salsalate

1 interaction

Monitor/Modify Tx

lisdexamfetamine + salsalate

monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

• selpercatinib
Arynta (lisdexamfetamine)

+

selpercatinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + selpercatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• sevoflurane
Arynta (lisdexamfetamine)

+

sevoflurane

1 interaction

Monitor/Modify Tx

lisdexamfetamine + sevoflurane

consider D/C lisdexamfetamine day of surgery: combo may incr. risk of intraoperative HTN, tachycardia (mechanism unknown)

• siponimod
Arynta (lisdexamfetamine)

+

siponimod

1 interaction

Monitor/Modify Tx

lisdexamfetamine + siponimod

monitor BP: combo may incr. risk of HTN (additive effects)

• solriamfetol
Arynta (lisdexamfetamine)

+

solriamfetol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + solriamfetol

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• sorafenib
Arynta (lisdexamfetamine)

+

sorafenib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + sorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

• spironolactone
Arynta (lisdexamfetamine)

+

spironolactone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + spironolactone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• sulindac
Arynta (lisdexamfetamine)

+

sulindac

1 interaction

Monitor/Modify Tx

lisdexamfetamine + sulindac

monitor BP: combo may incr. risk of HTN (additive effects)

• sunitinib
Arynta (lisdexamfetamine)

+

sunitinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + sunitinib

monitor BP: combo may incr. risk of HTN (additive effects)

• tacrolimus
Arynta (lisdexamfetamine)

+

tacrolimus

1 interaction

Monitor/Modify Tx

lisdexamfetamine + tacrolimus

monitor BP: combo may incr. risk of HTN (additive effects)

• tagraxofusp
Arynta (lisdexamfetamine)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

lisdexamfetamine + tagraxofusp

monitor BP: combo may incr. risk of HTN (additive effects)

• telmisartan
Arynta (lisdexamfetamine)

+

telmisartan

1 interaction

Monitor/Modify Tx

lisdexamfetamine + telmisartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terazosin
Arynta (lisdexamfetamine)

+

terazosin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + terazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terbutaline
Arynta (lisdexamfetamine)

+

terbutaline

1 interaction

Monitor/Modify Tx

lisdexamfetamine + terbutaline

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• teriflunomide
Arynta (lisdexamfetamine)

+

teriflunomide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + teriflunomide

monitor BP: combo may incr. risk of HTN (additive effects)

• testosterone
Arynta (lisdexamfetamine)

+

testosterone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + testosterone

monitor BP: combo may incr. risk of HTN (additive effects)

• thyroid
Arynta (lisdexamfetamine)

+

thyroid

1 interaction

Monitor/Modify Tx

lisdexamfetamine + thyroid

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• timolol
Arynta (lisdexamfetamine)

+

timolol

1 interaction

Monitor/Modify Tx

lisdexamfetamine + timolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• tivozanib
Arynta (lisdexamfetamine)

+

tivozanib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + tivozanib

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• tolmetin
Arynta (lisdexamfetamine)

+

tolmetin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + tolmetin

monitor BP: combo may incr. risk of HTN (additive effects)

• torsemide
Arynta (lisdexamfetamine)

+

torsemide

1 interaction

Monitor/Modify Tx

lisdexamfetamine + torsemide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• trametinib
Arynta (lisdexamfetamine)

+

trametinib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + trametinib

monitor BP: combo may incr. risk of HTN (additive effects)

• trandolapril
Arynta (lisdexamfetamine)

+

trandolapril

1 interaction

Monitor/Modify Tx

lisdexamfetamine + trandolapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• triamcinolone
Arynta (lisdexamfetamine)

+

triamcinolone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + triamcinolone

monitor BP: combo may incr. risk of HTN (additive effects)

• triamterene
Arynta (lisdexamfetamine)

+

triamterene

1 interaction

Monitor/Modify Tx

lisdexamfetamine + triamterene

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• trospium
Arynta (lisdexamfetamine)

+

trospium

1 interaction

Monitor/Modify Tx

lisdexamfetamine + trospium

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ubrogepant
Arynta (lisdexamfetamine)

+

ubrogepant

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ubrogepant

monitor BP: combo may incr. risk of HTN (additive effects)

• vadadustat
Arynta (lisdexamfetamine)

+

vadadustat

1 interaction

Monitor/Modify Tx

lisdexamfetamine + vadadustat

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• valsartan
Arynta (lisdexamfetamine)

+

valsartan

1 interaction

Monitor/Modify Tx

lisdexamfetamine + valsartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• vamorolone
Arynta (lisdexamfetamine)

+

vamorolone

1 interaction

Monitor/Modify Tx

lisdexamfetamine + vamorolone

monitor BP: combo may incr. risk of HTN (additive effects)

• vandetanib
Arynta (lisdexamfetamine)

+

vandetanib

1 interaction

Monitor/Modify Tx

lisdexamfetamine + vandetanib

monitor BP: combo may incr. risk of HTN (additive effects)

• vasopressin
Arynta (lisdexamfetamine)

+

vasopressin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + vasopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• verapamil
Arynta (lisdexamfetamine)

+

verapamil

1 interaction

Monitor/Modify Tx

lisdexamfetamine + verapamil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• vilanterol inhaled
Arynta (lisdexamfetamine)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

lisdexamfetamine + vilanterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• viloxazine
Arynta (lisdexamfetamine)

+

viloxazine

1 interaction

Monitor/Modify Tx

lisdexamfetamine + viloxazine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• voclosporin
Arynta (lisdexamfetamine)

+

voclosporin

1 interaction

Monitor/Modify Tx

lisdexamfetamine + voclosporin

monitor BP: combo may incr. risk of HTN (additive effects)

• zavegepant
Arynta (lisdexamfetamine)

+

zavegepant

1 interaction

Monitor/Modify Tx

lisdexamfetamine + zavegepant

monitor BP: combo may incr. risk of HTN (additive effects)

• ziv-aflibercept
Arynta (lisdexamfetamine)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

lisdexamfetamine + ziv-aflibercept

monitor BP: combo may incr. risk of HTN (additive effects)